Nose to Brain Delivery of Nanocarriers Towards Attenuation of Demented Condition

Author(s): Bapi Gorain*, Davinaa C. Rajeswary, Manisha Pandey, Prashant Kesharwani, Santosh A. Kumbhar, Hira Choudhury*.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 19 , 2020

Become EABM
Become Reviewer


Increasing incidence of demented patients around the globe with limited FDA approved conventional therapies requires pronounced research attention for the management of the demented conditions in the growing elderly population in the developing world. Dementia of Alzheimer’s type is a neurodegenerative disorder, where conventional therapies are available for symptomatic treatment of the disease but possess several peripheral toxicities due to lack of brain targeting. Nanotechnology based formulations via intranasal (IN) routes of administration have shown to improve therapeutic efficacy of several therapeutics via circumventing blood-brain barrier and limited peripheral exposure. Instead of numerous research on polymeric and lipid-based nanocarriers in the improvement of therapeutic chemicals and peptides in preclinical research, a step towards clinical studies still requires wide-ranging data on safety and efficacy. This review has focused on current approaches of nanocarrierbased therapies on Alzheimer’s disease (AD) via the IN route for polymeric and lipid-based nanocarriers for the improvement of therapeutic efficacy and safety. Moreover, the clinical application of IN nanocarrier-based delivery of therapeutics to the brain needs a long run; however, proper attention towards AD therapy via this platform could bring a new era for the AD patients.

Keywords: Alzheimer's disease, intranasal, olfactory, polymeric nanoparticles, lipid-based nanocarriers, clinical perspective.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [2233 - 2246]
Pages: 14
DOI: 10.2174/1381612826666200313125613
Price: $65

Article Metrics

PDF: 12